Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Efficacy and Safety of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus

ClinicalTrials.gov ID: NCT02446899

Public ClinicalTrials.gov record NCT02446899. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 12:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate the efficacy and safety of an intravenous treatment regimen of anifrolumab versus placebo in adult participants with moderately to severely active, autoantibody-positive systemic lupus erythematosus (SLE).

Study identification

NCT ID
NCT02446899
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
AstraZeneca
Industry
Enrollment
373 participants

Conditions and interventions

Interventions

Biological · Drug

Eligibility (public fields only)

Age range
18 Years to 70 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 8, 2015
Primary completion
Sep 26, 2018
Completion
Sep 26, 2018
Last update posted
Jan 9, 2023

2015 – 2018

United States locations

U.S. sites
35
U.S. states
17
U.S. cities
31
Facility City State ZIP Site status
Research Site Covina California 91723
Research Site Hemet California 92543-4403
Research Site Los Angeles California 90095
Research Site San Leandro California 94578
Research Site Torrance California 90509
Research Site Upland California 91786
Research Site Denver Colorado 80230
Research Site Bridgeport Connecticut 06606
Research Site Bridgeport Connecticut 6606
Research Site Brandon Florida 33511
Research Site Orlando Florida 32804
Research Site Palm Harbor Florida 34684
Research Site Tamarac Florida 33321
Research Site Tampa Florida 33614
Research Site Atlanta Georgia 30303
Research Site Boston Massachusetts 02118
Research Site Ann Arbor Michigan 48109
Research Site Lincoln Nebraska 68516
Research Site Las Cruces New Mexico 88011
Research Site Brooklyn New York 11201
Research Site New York New York 10016
Research Site New York New York 10021
Research Site New York New York 10032
Research Site Greenville North Carolina 27834
Research Site Oklahoma City Oklahoma 73104
Research Site Duncansville Pennsylvania 16635
Research Site Pittsburgh Pennsylvania 15213
Research Site Memphis Tennessee 38163
Research Site Dallas Texas 75231
Research Site Houston Texas 77004
Research Site Houston Texas 77034
Research Site Stafford Texas 77477
Research Site Arlington Virginia 22205
Research Site Seattle Washington 98122
Research Site Spokane Washington 99204

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 78 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02446899, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 9, 2023 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02446899 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →